Pramana
Let's address the ripple effect of Hypoglycemia
Pipeline
Improving lives targeting a new mechanism of action to treat metabolic dysregulation via an immune response.
Diabetes & Obesity
One person dies from Diabetes and its complications every eight seconds and Obesity is the cause of nearly 1 out of 5 adult deaths Over 40% of the U.S. population is living with Obesity and minority group members are disproportionally impacted In the US with fewer than 3% being pharmacologically treated for obesity. The economic impact associated with Obesity is over $1 trillion dollars. We are advancing a
novel oral undisclosed therapy in Obesity with a target product profile
that we feel will meet a large unmet need in the space.
PRM A Hypoglycemia
Hypoglycemia affects over 100 million people. It is prevalent in 90% of T1D patients and 25% of T2DM patients. Severe hypoglycemia can lead to death. There is no preventative treatment. PRM A has shown significant and differentiating glucagon response. PRM A acts as a smart modulator that auto-adjusts sugar levels in the blood to achieve glycemic control by targeting a specific receptor.
NASH
Our R&D focus for liver and metabolic disease is NASH. Among the largest unmet medical needs globally, NASH and metabolic diseases represent a leading cause of morbidity and mortality and a significant burden for patients and healthcare systems. In the U.S. the annual cost burden is $103 billion and projected to exceed $1 trillion within 10 years.
Our molecular library has the potential to address this area of high unmet need . Our compounds have multiple pathways of interest which could assist in the regulation of cardio-metabolic processes and liver function.
Pramana